Merck gains FDA approval of hepatitis C drug Victrelis

The FDA approved Merck & Co.'s hepatitis C drug Victrelis, or boceprevir. The drug works by blocking an enzyme, protease, that the virus utilizes for replication. Vertex Pharmaceuticals also is expected to get FDA approval this month for its hepatitis C drug candidate. The New York Times (tiered subscription model)

source: AABBsmartbrief